Blood is a major necessity for patients suffering from injuries and viral infections, which require blood transfusion. The patients are either given whole blood or blood components for quick recovery and healing, resulting into increased demand for blood banks.
The global blood market was valued at $33,500 million in 2016, and is estimated to reach $45,982 million by 2023, registering a CAGR of 4.6% from 2017 to 2023. The major factors that enhance the market growth are increase in geriatric population, rise in trauma cases, technological advancement in medical technology for donor screening, and advancement in blood transfusion instruments. However, rise in minimal invasive technology, which no longer requires blood transfusion restrains the market growth.
The global blood market is segmented by product, end user, and geography. Based on product, it is divided into whole blood collection, source plasma collection, blood therapeutics, blood typing products, blood screening, and blood processing equipment & associated products. Blood therapeutics segment contributed the highest share in 2016, owing to the increase in the demand for various plasma proteins for the recovery of patients. Based on whole blood collection, the market is bifurcated into system and reagents. On the basis of source plasma collection, it is divided into system and reagents. Blood therapeutics are categorized into intravenous immunoglobulin (IVIG), factor IX, factor VIII, hyperimmune, and albumins. Blood typing products are classified into system and reagents. Blood screening is further divided into systems and reagents. Blood processing equipment & associated products are categorized into systems and reagents.
Geographically, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. The North America market accounted for significant share in the global market in 2016, owing to a well-developed healthcare industry and rise in number of patient population requiring blood & blood components.
KEY BENEFITS
The study provides an in-depth analysis of the global blood market, with the current trends and future estimations to elucidate the imminent investment pockets.
The report provides quantitative analysis of the industry from 2016 to 2023 to enable stakeholders to capitalize on the prevailing opportunities.
Extensive analysis of the market based on the product and end user elucidates the prevailing opportunities in these segments.
Comprehensive analysis of geographical regions is provided to determine the latent regional opportunities.
Key players operating in the market and their strategies are profiled to determine the competitive outlook of the market.
KEY MARKET SEGMENTS
BY PRODUCT
Whole Blood Collection
Whole Blood Collection Systems
Whole Blood Collection Reagents
Source Plasma Collections
Source Plasma Collection Systems
Source Plasma Collection Reagents
Blood Therapeutics
IVIG (Intravenous Immunoglobulin)
Factor IX
Factor VIII
Hyperimmune
Albumins
Blood Typing Products
Blood Typing Systems
Blood Typing Reagents
Blood Screening
Blood Screening Systems
Blood Screening Reagents
Blood Processing Equipment & Associated Products
Blood Processing Equipment Systems
Blood Processing Equipment Reagents
BY END USER
Blood & Blood Component Bank
Diagnostic Laboratories
Ambulatory Surgical Centers
Hospitals
Others (Academic Institutes & Research Laboratories)
BY GEOGRAPHY
North America
U.S.
Canada
Mexico
Europe
UK
France
Germany
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Rest of Asia-Pacific
LAMEA
Latin America
Middle East
Africa
LIST OF KEY PLAYERS PROFILED IN THE REPORT
Abbott Laboratories
Becton, Dickinson & Co.
Baxter International Inc.
CSL Behring
Grifols International SA
Immucor
Novartis
Novo Nordisk
Ortho Clinical Diagnostics
Roche Diagnostics
LIST OF OTHER PLAYERS IN THE VALUE CHAIN
(These players are not profiled in the report, but can be included on request)
Medimmune (AstraZeneca)
Fresenius Kabi
Macopharma
Nipro Medical Corporation
Sarstedt AG & Co.
Thermo Fisher Scientific, Inc.
